<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>AIMS/HYPOTHESIS: Non-alcoholic <z:hpo ids='HP_0001397'>fatty liver</z:hpo> disease (NAFLD) is common in type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> but it is unknown whether NAFLD is prevalent in European women at risk of type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> </plain></SENT>
<SENT sid="1" pm="."><plain>We studied the prevalence of, and risk factors for, NAFLD in European women with previous <z:hpo ids='HP_0009800'>gestational diabetes</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">GDM</z:e>) at high risk of type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> </plain></SENT>
<SENT sid="2" pm="."><plain>METHODS: A total of 110 women with previous <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">GDM</z:e> and 113 without previous <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">GDM</z:e>, with non-diabetic <z:chebi fb="105" ids="17234">glucose</z:chebi> tolerance were recruited retrospectively from antenatal databases </plain></SENT>
<SENT sid="3" pm="."><plain>Participants underwent liver ultrasound scan examination, anthropometry and blood sampling for liver function tests and to determine levels of fasting <z:chebi fb="23" ids="18059">lipids</z:chebi>, NEFA and insulin and <z:chebi fb="105" ids="17234">glucose</z:chebi> concentrations in order to derive insulin sensitivity and insulin secretion indices (HOMA%S and HOMA%B, respectively) </plain></SENT>
<SENT sid="4" pm="."><plain>RESULTS: There was no significant difference in BMI in women with previous <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">GDM</z:e> compared with those without previous <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">GDM</z:e> (28.9 ± 0.6 vs. 27.9 ± 0.6 kg/m(2), respectively; p =��0.12) </plain></SENT>
<SENT sid="5" pm="."><plain>Women with previous <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">GDM</z:e> had higher fasting and 2 h <z:chebi fb="105" ids="17234">glucose</z:chebi> concentrations following a 75 g OGTT ([mean ± <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">SEM</z:e>] fasting <z:chebi fb="105" ids="17234">glucose</z:chebi> 5.3 ± 0.1 vs. 5.1 ± 0.1 mmol/l, p = 0.02; 2 h <z:chebi fb="105" ids="17234">glucose</z:chebi> 6.8 ± 0.2 vs. 5.8 ± 0.3 mmol/l, p = 0.02), <z:e sem="disease" ids="C0242339" disease_type="Disease or Syndrome" abbrv="">dyslipidaemia</z:e> (<z:chebi fb="1" ids="47774">LDL-cholesterol</z:chebi> 3.3 ± 0.1 vs. 2.8 ± 0.1 mmol/l; <z:chebi fb="4" ids="47775">HDL-cholesterol</z:chebi> [median {interquartile range}] 1.3 [1.2-1.6] vs. 1.8 [1.5-1.9] mmol/l; triacylglycerol 1.3 [0.9-1.6] vs. 1.0 [0.7-1.7] mmol/l, <z:hpo ids='HP_0000001'>all</z:hpo> p ≤ 0.03), higher insulin secretion and lower insulin sensitivity </plain></SENT>
<SENT sid="6" pm="."><plain>NAFLD prevalence was greater in women with previous <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">GDM</z:e> compared with those without previous <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">GDM</z:e>: 38% (95% CI 28-47%) vs. 17% (95% CI 10-24%), p = 0.001 </plain></SENT>
<SENT sid="7" pm="."><plain>In multiple logistic regression analysis, lower insulin sensitivity and raised serum alanine transaminase concentrations were associated with NAFLD </plain></SENT>
<SENT sid="8" pm="."><plain>CONCLUSIONS/INTERPRETATION: NAFLD is prevalent in European women with previous <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">GDM</z:e> </plain></SENT>
<SENT sid="9" pm="."><plain>Impaired insulin sensitivity and increased liver transaminase activity are closely associated with NAFLD in these women </plain></SENT>
</text></document>